Trial Profile
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations and Change in Lung Function in Patients (12-75 years of age) with Eosinophilic Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jul 2023
Price :
$35
*
At a glance
- Drugs Reslizumab (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms BREATH
- Sponsors Cephalon; Teva Branded Pharmaceutical Products R&D
- 24 May 2023 Meta analysis from NCT01000506, NCT01691521, NCT01287039, NCT01285323, NCT01928771, and NCT01914757, presented at the 119th International Conference of the American Thoracic Society.
- 25 Feb 2019 Results of pooled analysis of two phase III studies presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 25 Feb 2019 Results of pooled data from two 52-week placebo-controlled phase 3 trials of IV reslizumab assessing rates of complete exacerbation response presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology